SUPPLY CHAIN
“ Initiatives can be led by pharma companies , by the broader industry , or by policymakers and regulatory bodies ”
OLAF ZWEIG LIFE SCIENCES PARTNER EY-PARTHENON
be unlikely to significantly enhance any of the other aspects of resilience ”. In practice , the merits of localisation must be assessed “ relative to alternative options that exist for bolstering pharma supply resilience ”.
Such measures might include industrylevel initiatives , such as a procurement clearing house or joint warehouses , company-level measures like multiple sourcing of raw materials , or government-level steps , such as shortening regulatory processing timelines .
Wearable digital devices are among
“ Multiple plausible approaches the tech developments helping exist businesses ,” says Zweig speed . delivery “ Initiatives and can be manage led by customer an individual expectation pharma
The global pharmaceutical industry had annual revenue of
$ 1.42tn in 2021
company , by the broader industry working collaboratively or by policymakers and regulatory bodies interacting with pharma and having a stake in the future of its supply chain operations .”
He concludes : “ Greater collaboration and cooperation between pharma and its stakeholders will be key to successfully building resilient and sustainable supply chains for the future , and delivering the outcomes sought by patients and by all parties in the ecosystem that serve them . But it ’ s important to say there is no single nor simple path forward from this point .”
52 July 2023